Inovio reports postive results for cervical cancer vaccine tests

Inovio Pharmaceuticals, Inc., a developer of DNA vaccines, reported on September 13 that it has received best-in-class immune responses in its Phase I dose escalation study of its cervical cancer vaccine.

The vaccine - VGX-3100 - is a DNA vaccine tailored to treat pre-cancerous cervical dysplasias and cervical cancers caused by the human papillomavirus, according to

The vaccine, which targets HPV E6 and E7 proteins, is delivered via in vivo electroporation.

The escalation study, according to the company, tested the immunogenicity and safety of VGX-3100 in women who had been previously treated for moderate or severe cervical intraepithelial neoplasia, which is a high-grade premalignant lesion that often leads to cervical cancer.

All of the tested groups developed significant T-cell and antibody immune responses and in the third and final dose group, 83 percent developed previously unheard of T-cell responses that have not been seen with other non-replicating vaccine platforms in humans, according to Inovio.

Inovio plans to conduct a blinded, randomized, Phase II study of VGX-3100 in the first part of 2011.

In addition to its HPV research, Inovio's clinical programs include avian flu and HIV vaccines. Inovio is developing its universal influenza vaccines in collaboration with scientists from the University of Pennsylvania and National Microbiology Laboratory of the Public Health Agency of Canada.

Its other partners include Merck, the National Cancer Institute, HIV Vaccines Trial Network and the PATH Malaria Vaccine Initiative.